Sanofi Industry Developments July 2026: Novo Nordisk received CDSCO approval for Wegovy (semaglutide) as the first and only GLP-1 receptor agonist approved in India for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, expanding the drug's indication beyond weight management and type 2 diabetes
CreaT1 is essential for normal brain and muscular function as mutations in the gene (SLC6A8) result in X-linked mental retardation, severe speech and language delay, epilepsy, autistic behavior, and muscular abnormalities (e.g., hypotonia) (Bala et al
But recent research shows that allulose , the low-calorie, low-carb sweetener we use in every Two Spoons pint, may also stimulate the bodys natural GLP-1 release
Future interventions that selectively modulate neutrophil activation, ROS generation, or NET formationsuch as PAD4 inhibitors, ROS scavengers, DNase-based therapies, or blockade of neutrophilplatelet interactionshold promise to shift PCOS management from symptomatic hormone modulation toward precision immuno-metabolic therapy
In addition, ROS contribute to the maintenance of a proinflammatory state, secondary to secretion of cytokines and chemokines (Hsieh and Yang, 2013
